98 results about "Immune receptor" patented technology

Systems and methods to assess immune receptor sequences can incorporate a language model to yield embedded representations and classification of immune status. Classification systems and method can include assessment of embedded immune receptor sequence representations that account for isotype or V(D)J gene segment selection. Systems and methods to assess immunity status can incorporate one or more classifiers to predict immune status.

Provided herein are cytokine-immunoreceptor fusion proteins. Also provided herein are cells, polynucleotides, vectors, compositions, and methods directed to cytokine-immunoreceptor fusion proteins.

The disclosure provides synthetic immune receptors (SIRs), nucleic acids encoding the SIRs, methods of making and using the SIRs, in, for example, adoptive cell therapy.

Provided herein, among other things, is a cytotoxic immune cell (e.g., a cytotoxic T cell) that expresses an engineered immune receptor (such as a CAR or TCR) whose cytotoxicity within the tumor microenvironment is enhanced by a pro-inflammatory protein that is induced only when the cell binds to either a tissue-specific or cancer-associated antigen. As such, the present cells can be used for the treatment of cancers that are associated with solid tumors.

The present invention discloses a method for predicting adaptive immune receptors by integrating gene and sequence information, comprising the following steps: S1, modifying the SC-AIR-BERT model to construct an SC-AIR-BERT-Multi model; the SC-AIR-BERT-Multi model comprises a gene information extraction channel, a sequence information extraction channel, a multimodal fusion module, and two multi-layer perceptrons for multi-task learning; S2, in the gene information extraction channel, using the gene name as input, obtaining the gene feature h of the immune cell receptor gene ; S3, in the sequence information extraction channel, using TCR sequence or BCR sequence as input, obtain the sequence feature h of immune cell receptor seq ; S4, the gene features and sequence features of the V, D, and J gene segments are sent to the multimodal feature fusion module for fusion, and the fused features are generated; S5, the multimodal receptor feature Representation learned in step S4 is mapped to the final TCR or BCR antigen binding specificity prediction and affinity prediction results through two multi-layer perceptrons for prediction.

Compositions and methods are disclosed for uniquely tagging each rearranged gene segment that encodes a T cell receptor (TCR) and / or an immunoglobulin (Ig), in a DNA (or mRNA or cDNA reverse transcribed therefrom) sample from lymphoid cells. These and related embodiments permit accurate, high throughput quantification of distinct TCR and / or Ig encoding sequences. Also provided are compositions and methods for quantitatively sequencing the genes that encode both chains of a TCR or Ig heterodimer in a single cell, for example, to characterize the degree of T or B cell clonality in a sample.

The invention belongs to the technical field of biological medicines, and particularly relates to bacillus velezensis and application thereof in preventing and treating inflammatory bowel diseases. The bacillus velezensis GFZF-23 provided by the invention is preserved in the China Center for Type Culture Collection, and the preservation number of the bacillus velezensis GFZF-23 is CCTCC (China Center for Type Culture Collection) NO: M 20251699. The bacillus velezensis GFZF-23 can be used for effectively treating the inflammatory bowel disease by reducing the pathological injury of intestinal tissues, reducing the expression of inflammatory factors and immune receptor genes, enhancing the expression of related genes of intestinal mucosal barriers and remodeling the balance of intestinal flora. The invention provides a new treatment strategy for treating the inflammatory bowel disease, and has remarkable clinical application value and wide market prospect.

The present invention relates generally to a plant cell-surface immune receptor engineered to modulate an immune response in a plant, cell or seed, as well as nucleic acid molecules encoding the engineered receptor, and methods of use. In particular, the present invention relates to a plant cell-surface immune receptor into which a coiled-coil (CC) motif is integrated to enhance or modify the plant's immune response, with utility in reducing pathogen infection and improving pathogen resistance.

The present invention provides for an engineered, genetically modified, and / or synthetic plant receptor comprising a binding sequence that is capable of binding a fungal pathogen Avr ligand; wherein the non-engineered, genetically unmodified, and / or naturally occurring plant receptor does not bind the fungal pathogen Avr ligand, or bind with a lower binding affinity.

Methods are provided for predicting a subject's infection status using high-throughput T cell receptor sequencing to match the subject's TCR repertoire to a known set of disease-associated T cell receptor sequences. The methods of the present invention may be used to predict the status of several infectious agents in a single sample from a subject. Methods are also provided for predicting a subject's HLA status using high-throughput immune receptor sequencing.

Systems and methods for long-read sequencing of immune receptor are disclosed. A method in accordance with the present disclosure comprises generating a 3'-barcoded cDNA library comprising an immune receptor target sequence, wherein the immune receptor target sequence comprises a variable region and a barcoded region; amplifying the immune receptor target sequence; linking the variable region of the immune receptor target sequence to a probe to generate a labeled immune receptor target sequence; capturing the labeled immune receptor target sequence; amplifying the captured immune receptor target sequence; passing the captured immune receptor target sequence through a nanopore sequencing device; and generating, by way of the nanopore sequencing device, a full-length immune receptor target sequence.

The name of the invention is small shedding blockers. In some embodiments, less than 100 thousand Daltons of agents are provided that bind to a membrane immune receptor on the surface of a cell and inhibit protease cleavage of the immune receptor. Also provided are methods of treating cancer and enhancing immunotherapy comprising administering the agents.

The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.

Disclosed herein are methods, compositions, systems, and kits related to functional testing of polypeptide-target interactions, such as antigen / immune receptor interactions, in a single-cell format.

Disclosed are methods for determining the immunological status of the adaptive immune system of a subject by identifying and quantifying rearranged DNA (and / or subsequently transcribed RNA) sequences encoding T cell receptor (TCR) and / or immunoglobulin (IG) polypeptides, in a lymphoid DNA-containing sample from the subject. TCR and / or IG sequence diversity and sequence distribution permit immunocompetence and immune repertoire assessment and reflect the degree of T cell or B cell clonality and clonal expansion in the sample. Methods for stratifying patient populations on the basis of immunocompetence including likelihood of responding to immunotherapy are also described.

The invention relates to the technical field of medical engineering, in particular to an NK cell delivery data processing method and system based on magnetic targeting. The method comprises the following steps: inquiring an immune receptor protein structure of natural killer cells; injecting a sodium chloride solution, adding an immune receptor protein structure, and reacting to generate an aptamer structure; the method comprises the following steps: combining streptavidin in a pre-prepared glycosyl magnetic microsphere to obtain a high-affinity magnetic bead; carrying out molecular docking on the high-affinity magnetic beads and the aptamer structure, recording a docking score, and generating an optimized aptamer; recording the magnetic bead mass ratio of the optimized aptamer; capturing the natural killer cells by adopting the optimized aptamer, and shooting to obtain a fluorescent microscopic image; and recording the dyeing condition of the fluorescent microscopic image, determining the survival state of the NK cells, marking the position information of the living cells, and generating an NK cell delivery efficiency table by using the mass ratio of the magnetic beads. Based on a medical engineering technology, the homing rate and the delivery efficiency of the NK cells at the liver injury part are improved.

The present invention relates to lactolipoprotein subfamily 2 member A1 (BTN2A1) binding peptides wherein the amino acid sequence comprises amino acids other than glutamic acid, such as tryptophan, at a position corresponding to position 22 shown in SEQ ID NO: 1; an amino acid other than arginine at a position corresponding to position 73 shown in SEQ ID NO: 1, such as tyrosine; and / or an amino acid other than threonine at a position corresponding to position 81 shown in SEQ ID NO: 1, such as histidine or tryptophan. The BTN2A1 binding peptide may be included in a (exogenous) immune receptor or an extracellular domain thereof, preferably a gamma delta T cell receptor or an extracellular domain thereof, more preferably a gamma 9 delta 2T cell receptor or an extracellular domain thereof. The invention relates, inter alia, to the use in the treatment, preferably in the treatment of cancer and / or infection, or in diagnostic methods.

Disclosed herein is a method for enhancing adoptively transferred autologous or allogeneic immune effector T-cells (including gamma delta T cells (γδ-T cells)) by targeting the thioredoxin (TRX)-interacting protein (TXNIP). In addition, disclosed herein are cDNA sequences for the co-expression of immune receptors (CARs, TCRs, etc) in combination with guide RNAs, and / or artificial or natural microRNAs, and / or shRNAs targeting TXNIP.

The present invention provides adoptive T cell therapy with improved structures for targeting antigens and recruiting multimeric immune signaling complexes to treat, prevent, or ameliorate at least one symptom of cancer, infectious disease, autoimmune disease, inflammatory disease, and immune deficiency, or conditions associated therewith. The present disclosure relates generally to engineered immune receptor complexes capable of recognizing a target antigen and recruiting and activating natural or transgenic immune receptor signaling complexes, e.g., T cell receptor (TCR) signaling complexes, polynucleotides and polypeptides encoding same, compositions thereof, and methods of making and using same to treat a disorder or disease (e.g., cancer or autoimmunity).

Provided herein is a recombinant polypeptide comprising: the transmembrane domain of FcεR1γ or CD3ζ, or a variant of the transmembrane domain that retains the ability to bind to NKp30, NKp46 and / or CD16, a co-stimulatory domain, and one or more immunoreceptor tyrosine-based activation motifs (ITAMs). Cells expressing the same and methods of treatment are also provided.

Described herein are techniques for predicting whether a subject will experience an immune-related adverse event (irAE) in response to administration of an immune checkpoint inhibitor (ICI) therapy. In some embodiments, the techniques include: determining a likelihood that the subject will experience the irAE in response to administration of the ICI therapy, the determining comprising: performing: (a) processing clinical data using a first machine learning (ML) model to output a first likelihood that the subject will experience the irAE, (b) processing RNA sequencing data using a second ML model to output a second likelihood that the subject will experience the irAE, and / or (c) processing immune receptor data using a third ML model to output a third likelihood that the subject will experience the irAE; and processing the first, second, and / or third likelihoods using a fourth ML model trained to predict the likelihood that the subject will experience the irAE.

Disclosed is a Butyrophilin Subfamily 2 Member A1 (BTN2A1) binding peptide with an amino acid sequence comprising an amino acid other than glutamic acid, for example, tryptophan, at a position corresponding to position 22 shown in SEQ ID NO: 1; an amino acid other than arginine, for example, tyrosine, at a position corresponding to position 73 shown in SEQ ID NO: 1; and / or an amino acid other than threonine, for example, histidine or tryptophan, at a position corresponding to position 81 shown in SEQ ID NO: 1. The BTN2A1 binding peptide may be comprised in an (exogeneous) immune receptor or extracellular domain thereof, preferably a γδ T-cell receptor or extracellular domain thereof, more preferably a γ9δ2 T-cell receptor or extracellular domain thereof. This disclosure particularly relates to use in therapy, preferably for use in treatment of a cancer and / or an infection, or for use in diagnostic methods.

Provided herein, among other things, is a cell-based therapeutic for the treatment of a non-malignant disease of the lung. In some embodiments, the therapeutic may comprise a cell comprising a molecular circuit comprising: (i) a binding-triggered transcriptional switch (BTTS) that binds to RAGE (Receptor for Advanced Glycation Endproducts), (ii) a nucleic acid sequence encoding an immunosuppressive protein, a growth factor and / or an anti-fibrotic agent; and (iii) a regulatory sequence operably linked to (ii) that is responsive to the binding-triggered transcriptional switch, wherein binding of the binding-triggered transcriptional switch to RAGE activates expression of the immunosuppressive protein, growth factor and / or the anti-fibrotic agent in the lung. Alternatively or in addition, the therapeutic may be a T cell (Treg) comprising an engineered immune receptor that recognizes RAGE. Also provided is a method for decreasing inflammation in the lung and / or inducing repair of lung tissue.

The present disclosure provides compositions and methods for delivering an engineered immune receptor to immune cells, e.g., T cells, in vivo, ex vivo, or in vitro. Provided are recombinant nucleic acids and templates that are useful for immune cell reprogramming with high specificity and efficiency.

Provided herein are compositions and methods for increasing the amount aryl-lactates in fermented foods. The methods can comprise delivering alpha-ketoglutarate (AKG), trisodium citrate dehydrate (CIT), or both AKG and CIT; and / or phenylpyruvic acid (PPyA), 4-hydroxyphenylpyruvic acid (4HPPyA), indole-3-pyruvic acid (IPyA) or combinations thereof; and / or phenylalanine (Phe), tyrosine (Tyr), and / or tryptophan or combinations thereof to fermented foods and fermented food matrices. Optionally, bacteria with aromatic amino transferase (ArAT) and / or phenyllactate dehydrogenase activity can also be added to the fermented foods and fermented food matrices. Also provided are methods to increase the bioactivity of fermented foods towards an immune receptor (aryl hydrocarbon receptor—AhR). Also provided are methods to more effectively maintain food matrix AhR bioactivity across food storage times of up to 4 weeks. Also provided are methods of inducing weight loss, reducing fat mass, and / or reducing glucose intolerance in mammals.

The invention relates to immune receptor barcode error correction. Disclosed herein are methods and systems for determining the presence of a target. In some embodiments, the method includes: folding an estimated sequence of the targets; folding a molecular marker sequence associated with the estimated sequence of the target; and estimating the appearance of the target, where after folding the appearance of the estimated sequence of the target and folding the appearance of a noise molecular marker sequence, the estimated appearance of the target correlates with the appearance of a molecular marker sequence associated with the estimated sequence of the target in the sequencing data.

To provide antibodies that specifically bind to TIGIT (T cell immune receptor with Ig and ITIM domains).SOLUTION: Disclosed is an antibody or antigen binding fragment thereof capable of binding human TIGIT, the antibody comprising: (a) a heavy variable region (VH) comprising one, two or three CDR amino acid sequences selected from specified amino acid sequences; and / or (b) a light variable region (VL) comprising one, two or three CDR amino acid sequences selected from other specified amino acid sequences.SELECTED DRAWING: None

Disclosed herein are nanoparticle conjugates (e.g., anti-angiogenic and / or immunomodulatory nanoparticle conjugates, e.g., high-affinity Designed Ankyrin Repeat Protein (DARPin)-based binders targeting one or more cancer and / or immune receptors). The nanoparticle conjugates are useful for therapeutics and / or diagnostics and have a diameter (e.g., average diameter) no greater than 20 nanometers (e.g., as measured by dynamic light scattering (DLS) in aqueous solution, e.g., saline solution).

Methods of treating cancer or increasing, enhancing or stimulating an immune response with antibodies and antigen-binding fragments thereof that specifically bind to TIGIT (T cell immune receptor with Ig and ITIM domains, WUCAM, or Vstm3) in combination with an anti-PD1 antibody are provided.

The present invention provides a monoclonal antibody that recognizes human nectin 4 (Nectin4) with high affinity and specificity and inhibits its binding to T cell immune receptor (TIGIT) with Ig and ITIM domains. The present invention also provides a pharmaceutical composition comprising the antibody and a method for using them in cancer immunotherapy and diagnosis.